Investor Presentaiton

Innovative R&D - Co-development Co-development cases: Deepen international collaboration, accessing cutting edge technologies Yi Kai Da (Axicabtagene Ciloleucel Injection) became the first CAR-T cell therapy product approved for launch in China in June 2021 Indication Expansion Significant needs i potential as moving from third-line treatment to second-line treatment • Commercialization ~ 90,000 new NHL patients in China each year, 10,000 patients with third-line treatment* LBCL third-line therapy: Yi Kai Da became the first CAR-T cell therapy product approved for launch in China in June 2021 Yescarta launched in the U.S. in October 2017 LBCL second-line therapy: Yescarta became the world's first CAR-T cell therapy product approved by FDA for LBCL second- line therapy Yi Kai Da was approved for LBCL second-line therapy clinical trials by NMPA in August 2022 Yescarta (ZUMA-1): 5yrs OS 42.6%; for CR patients, 5yrs OS 64.4% Multicenter Clinical Trial in China for Bridging Study: ORR 79.2% Yescarta (ZUMA-7): Yescarta vs. SOC in second-line therapy of r/r DLBCL (Median follow-up: 24.9mths) ORR: 83% vs. 50%; CR: 65% vs. 32% Median EPS: 8.3mths vs. 2mths Established nearly 100 certified treatment centers and 10,000 m² GMP commercial manufacturing facility by the end of July 2022 Exploring diversified payment methods, including commercial insurance and citizen insurance. Yi Kai Da is included in over 50 commercial insurances and 44 citizen insurances by the end of July 2022. Product Pipeline The second indication r/r iNHL was granted Breakthrough Therapy Designation by the NMPA in August 2021 and the clinical trials in China are under process FDA approved Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) in July 2020; FKC889 for MCL is in the clinical stage in China Note*: source from Global Cancer Statistics 2018 23 1

View entire presentation